Skip to main content
  • Register
  • Help
  • Contact us

ChemoCentryx Inc (CCXI) USD0.001

Sell:$10.44 Buy:$10.46 Change: $17.03 (61.95%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$10.44
Buy:$10.46
Change: $17.03 (61.95%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$10.44
Buy:$10.46
Change: $17.03 (61.95%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Contact details

Address:
835 INDUSTRIAL ROAD, SUITE 600
SAN CARLOS
94070
United States
Telephone:
+1 (650) 2102900
Website:
www.chemocentryx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CCXI
ISIN:
US16383L1061
Market cap:
$1.92 billion
Shares in issue:
69.75 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Schall
    Chairman of the Board, President, Chief Executive Officer
  • Susan Kanaya
    Chief Financial and Administrative Officer, Executive Vice President, Secretary, Director
  • Tausif Butt
    Chief Operating Officer, Executive Vice President
  • Markus Cappel
    Chief Business Officer, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.